Gilead adds seladelpar, a PBC candidate now under priority review, to liver disease arsenal 

Deal positions Takeda to challenge Bristol Myers’ first-in-class Sotyktu 

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy, combos

Long-term, biomarkers will replace biopsies in NASH. Short-term, they’re aiding patient recruitment.